PharmaCyte Biotech Analyst Report Issued by BrokerBank Securities, Inc.
NEW YORK, Feb. 11, 2015 /PRNewswire/ -- PharmaCyte Biotech, Inc. (OTCQB: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
The company has just changed its name from Nuvilex to PharmaCyte Biotech on Jan 07, 2015. This name change is part of the company's transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box(R) technology, a proprietary cell encapsulation platform being utilized to develop "targeted" treatments for solid cancerous tumors and insulin dependent diabetes.
PharmaCyte Biotech has done multiple experiments of its Cell-in-a-Box technology on mice and pig cells, and the results were outstanding. The annual cost to treat diabetes in the U.S. alone is about $260 Billion. With the size of the market and a disruptive technology, PharmaCyte Biotech stands a chance to make a great leap in 2015, and its stock represents a great upside potential.
On January 29, 2015, PharmaCyte Biotech announced that its partner, Austrianova, has officially opened its new facilities at Synapse within Biopolis in Singapore. Biopolis is one of the world-class biomedical sciences hubs. The Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, attended the opening ceremonies.
On February 02, 2015, the firm initiated its first preclinical study to ensure the safety, efficacy and dosing of its proprietary Melligen cell line for the treatment of diabetes. With this act, PharmaCyte Biotech "officially" joined what has become an industry-wide search for a better solution to the fast-growing diabetes epidemic worldwide.
For the full research report with analyst comments on recent developments and recommendation on PMCB please follow the link. There is no cost obligation required to view analyst report:
http://bit.ly/-PMCB-AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Share this article